AI-GUIDED DRUG DISCOVERY
AI-guided competitive docking for virtual screening and compound efficacy prediction
Machine learning has revolutionized protein structure and interaction prediction, yet its full potential for drug discovery is still emerging. In this study, we show that denoise diffusion-based co-folding methods—such as AlphaFold3 and Boltz-1/2—not only achieve highly accurate protein-ligand interaction predictions but can also separate active compounds from inactive ones. We introduce a simple and effective strategy, pairwise competitive docking, which ranks candidate molecules by directly comparing their relative binding to a protein’s target site. Applied to 17 protein benchmark systems, the method generated rankings consistent with experimental trends, although the degree of agreement varied considerably by system, with concordance indices ranging from 0.52 (indicating no meaningful correlation) to 0.89 (indicating strong correlation). Notably, our rankings showed strong agreement with Boltz-2 affinity predictions, positioning our method as a practical alternative for inhibitor prioritization. Finally, we show how pairwise competitive docking can accelerate the identification of promising hits within a large chemical library and guide the de novo design of inhibitors with improved predicted potency. Collectively, these findings highlight how modern machine-learning models can make structure-based drug design faster, more reliable, and more cost-effective than relying solely on experimental workflows.
Executive Impact & Key Findings
Our AI-driven competitive docking strategy delivers unparalleled precision and efficiency for drug discovery.
Deep Analysis & Enterprise Applications
Select a topic to dive deeper, then explore the specific findings from the research, rebuilt as interactive, enterprise-focused modules.
Competitive Docking Workflow
| Feature | AI-guided Competitive Docking (AF3) | Direct AI-based Affinity Prediction (Boltz-2) |
|---|---|---|
| Core Mechanism |
|
|
| Pose Convergence |
|
|
| Rank Concordance |
|
|
| System Dependency |
|
|
| Clash Handling |
|
|
| Computational Cost |
|
|
| Hit Identification |
|
|
| De Novo Design |
|
|
Virtual Screening for DNA Gyrase Inhibitors
The All-at-Once strategy was applied to a library of 3155 FDA-approved molecules, including 46 Fluoroquinolones (FQs). This screening identified 147 top-ranking compounds, including 38 FQs, corresponding to a 25.9% enrichment. Applying additional filters based on pose convergence (cutoff of 2.5 Å) and proximity to the FQ binding site (cutoff of 2.0 Å) increased FQ enrichment to 77.8%. Tightening these thresholds to 1.0 Å further boosted enrichment to 93.5%, with an enrichment factor of 62. These results highlight the method's efficiency in accelerating hit identification.
De Novo Design of Potent FQs
Competitive docking was used to guide the design of more potent Fluoroquinolones (FQs). From several thousand automatically generated compounds using the STONED algorithm, 414 were selected. 31 newly designed compounds showed stronger binding potential than the reference STF, occupying the FQ binding site in at least 70% of the generated models. After filtering for favorable ADME properties, solubility, and synthetic accessibility, eight chemically novel candidates were identified, meriting future experimental validation. This demonstrates the method's potential in accelerating drug discovery through AI-guided molecular design.
Calculate Your Potential ROI
Estimate the significant time and cost savings AI-guided competitive docking can bring to your drug discovery pipeline.
Your Implementation Roadmap
Our phased approach ensures a seamless integration of AI-guided competitive docking into your existing workflows, maximizing impact with minimal disruption.
Phase 1: Discovery & Strategy
Initial consultation to understand your current drug discovery processes, target selection, and virtual screening needs. We'll identify key integration points and define success metrics tailored to your objectives.
Phase 2: Customization & Integration
Tailoring the competitive docking platform to your specific protein targets and chemical libraries. This includes data preparation, model fine-tuning, and seamless integration with your existing computational infrastructure.
Phase 3: Pilot & Optimization
Running pilot projects with your team to validate performance on relevant drug targets. We'll gather feedback, optimize parameters, and provide hands-on training to ensure your team is proficient with the new capabilities.
Phase 4: Scaling & Continuous Support
Full-scale deployment across your research teams, with ongoing support, performance monitoring, and regular updates to ensure you benefit from the latest advancements in AI-guided drug discovery.
Ready to Transform Your Drug Discovery?
Unlock the full potential of AI-guided competitive docking. Schedule a personalized consultation with our experts to explore how these advanced methods can accelerate your research and bring new therapeutics to market faster.